# OP-ED: Bias and Dysfunction in Cannabis Regulation at CBC > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/2026-cannabis-regulatory-dysfunction-impact/ > **Published:** 2026-03-28T23:02:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:01-04:00 > **Clinical Summary:** Explore how 2026 cannabis regulatory dysfunction affects patient access and product quality in medical cannabis oversight. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic RegulationPolicyProduct QualityPatient AccessClinical Practice Why This Matters Regulatory dysfunction at cannabis oversight bodies can directly impact patient access to standardized, quality-controlled cannabis medicines. When regulatory agencies face credibility challenges, it creates uncertainty in the therapeutic cannabis supply chain that clinicians and patients depend on. Clinical Summary This opinion piece discusses allegations of bias and dysfunction within a cannabis regulatory body, though specific clinical or scientific details are not provided in the summary. Regulatory instability in cannabis oversight can affect product testing standards, licensing consistency, and ultimately the reliability of cannabis products reaching patients. Without stable regulatory frameworks, clinicians face increased uncertainty about product quality and consistency when recommending cannabis therapeutically. Dr. Caplan’s Take “Regulatory chaos translates directly to clinical chaos — when oversight bodies are unstable, I lose confidence in the products I’m recommending to patients. Patients deserve consistent, reliable access to properly regulated [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), not products caught up in bureaucratic dysfunction.” Clinical Perspective 🧠 Clinicians should stay informed about regulatory changes in their jurisdiction that might affect cannabis product availability or standards. When regulatory uncertainty exists, consider discussing [alternative treatment](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) options with patients and emphasize the importance of sourcing products from established, reputable providers with transparent testing protocols. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20OP-ED%3A%20Allegations%20of%20bias%20and%20dysfunction%20are%20piling%20up%20at%20the%20CBC%20-%20Juno%20News%20%40drcaplan&url=https%3A//www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20OP-ED%3A%20Allegations%20of%20bias%20and%20dysfunction%20are%20piling%20up%20at%20the%20CBC%20-%20Juno%20News%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction](https://www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What type of cannabis-related topics does this article cover?](#What_type_of_cannabis-related_topics_does_this_article_cover) - [Who is the target audience for this cannabis news update?](#Who_is_the_target_audience_for_this_cannabis_news_update) - [Why is this cannabis news considered “emerging” information?](#Why_is_this_cannabis_news_considered_8220emerging8221_information) - [How does this update relate to patient care in medical cannabis?](#How_does_this_update_relate_to_patient_care_in_medical_cannabis) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has received a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the findings or policy developments are emerging and worth monitoring closely by healthcare professionals. #### What type of cannabis-related topics does this article cover? The article focuses on multiple key areas including regulation, policy developments, product quality standards, and patient access issues. These are all critical components of the evolving cannabis healthcare landscape. #### Who is the target audience for this cannabis news update? This update is primarily intended for healthcare professionals, particularly those at CED Clinic and other [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) practitioners. The clinical relevance rating system suggests it’s designed for medical professionals monitoring cannabis policy and regulatory changes. #### Why is this cannabis news considered “emerging” information? The article is marked as “New” and classified under “emerging findings or policy developments.” This indicates the information represents recent developments in cannabis regulation or policy that may impact clinical practice. #### How does this update relate to patient care in medical cannabis? The focus on patient access, product quality, and regulatory policy directly impacts how healthcare providers can prescribe and patients can obtain [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). These developments help ensure safe, regulated access to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “OP-ED: Allegations of bias and dysfunction are piling up at the CBC – Juno News”, “url”: “https://www.junonews.com/p/op-ed-allegations-of-bias-and-dysfunction”, “datePublished”: “2026-03-28T12:27:33Z”, “about”: “op ed allegations bias dysfunction piling”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [North Carolina advisory council recommends regulating 'wild west' cannabis market](https://cedclinic.com/north-carolina-cannabis-market-regulation-advisory-council/) Learn about regulatory recommendations aimed at taming unregulated cannabis markets to improve patient access and product quality. [Read More](https://cedclinic.com/north-carolina-cannabis-market-regulation-advisory-council/) [Debating medical marijuana oversight | newscentermaine.com](https://cedclinic.com/medical-marijuana-oversight-newscentermaine-com/) Explore ongoing debates about medical marijuana oversight and how regulatory frameworks affect clinical practice and patient safety. [Explore Article](https://cedclinic.com/medical-marijuana-oversight-newscentermaine-com/) [FDA's New Hemp CBD Enforcement Move Is Encouraging, But Congress Still Needs To …](https://cedclinic.com/fda-hemp-product-enforcement-cbd-regulation-impact/) Review recent FDA enforcement actions and their implications for hemp CBD regulation and patient access to quality products. [Learn More](https://cedclinic.com/fda-hemp-product-enforcement-cbd-regulation-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).